Gilead patents expiration
1. Cayston patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214364 | GILEAD | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
Dec, 2021
(2 years ago) | |
| US8399496 | GILEAD | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
Dec, 2021
(2 years ago) | |
| US7427633 | GILEAD | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
Dec, 2021
(2 years ago) | |
| US7208141 | GILEAD | Inhalable aztreonam aerosol for treatment and prevention of pulmonary bacterial infections |
Dec, 2021
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Feb 22, 2017 |
Drugs and Companies using AZTREONAM ingredient
Market Authorisation Date: 22 February, 2010
Treatment: Improve respiratory symptoms in cystic fibrosis in patients with pseudomonas aeruginosa
Dosage: FOR SOLUTION;INHALATION
CAYSTON family patents
2. Emtriva patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5814639 | GILEAD | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Sep, 2015
(8 years ago) | |
| US5914331 | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jul, 2017
(6 years ago) | |
| US6703396 | GILEAD | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar, 2021
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5814639 (Pediatric) | GILEAD | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Mar, 2016
(8 years ago) | |
|
US5914331 (Pediatric) | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jan, 2018
(6 years ago) | |
| US6642245 | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov, 2020
(3 years ago) | |
|
US6642245 (Pediatric) | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
May, 2021
(2 years ago) | |
|
US6703396 (Pediatric) | GILEAD | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Sep, 2021
(2 years ago) | |
Drugs and Companies using EMTRICITABINE ingredient
Market Authorisation Date: 28 September, 2005
Treatment: Treatment of hiv infection
Dosage: SOLUTION;ORAL; CAPSULE;ORAL
EMTRIVA family patents
3. Hepsera patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5663159 | GILEAD | Prodrugs of phosphonates |
Sep, 2014
(9 years ago) | |
| US6451340 | GILEAD | Nucleotide analog compositions |
Jul, 2018
(5 years ago) | |
Drugs and Companies using ADEFOVIR DIPIVOXIL ingredient
Market Authorisation Date: 20 September, 2002
Treatment: Therapy in chronic hepatitis b virus infection
Dosage: TABLET;ORAL
HEPSERA family patents
4. Letairis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5703017 | GILEAD | 3-(Het) arylcarboxylic acid derivatives, their preparation and intermediates for their preparation |
Dec, 2014
(9 years ago) | |
| US7109205 | GILEAD | Carboxylic acid derivatives, their preparation and use |
Oct, 2015
(8 years ago) | |
| US8349843 | GILEAD | Carboxylic acid derivatives, their preparation and use |
Oct, 2015
(8 years ago) | |
| USRE42462 | GILEAD | Carboxylic acid derivatives, their preparation and use |
Jul, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7601730 | GILEAD | Carboxylic acid derivatives, their preparation and use |
Oct, 2015
(8 years ago) | |
| US5840722 | GILEAD | Use of carboxylic acid derivatives as drugs |
Nov, 2015
(8 years ago) | |
| US8377933 | GILEAD | Method for treating a pulmonary hypertension condition |
Dec, 2027
(3 years from now) | |
| US9474752 | GILEAD | Method for treating a pulmonary hypertension condition |
Dec, 2027
(3 years from now) | |
| US9549926 | GILEAD | Compositions and methods of treating pulmonary hypertension |
Oct, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 15, 2012 |
| New Indication(I-716) | Oct 02, 2018 |
| Orphan Drug Exclusivity(ODE) | Jun 15, 2014 |
Drugs and Companies using AMBRISENTAN ingredient
NCE-1 date: 16 June, 2011
Market Authorisation Date: 15 June, 2007
Treatment: Method to treat pulmonary hypertension by administering ambrisentan to a patient; Method of inhibiting enthothelin receptors by administering ambrisentan to a patient to treat pulmonary arterial hyper...
Dosage: TABLET;ORAL
LETAIRIS family patents
5. Truvada patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5814639 | GILEAD | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Sep, 2015
(8 years ago) | |
| US5914331 | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jul, 2017
(6 years ago) | |
| US5977089 | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(6 years ago) | |
| US5922695 | GILEAD | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jul, 2017
(6 years ago) | |
| US5935946 | GILEAD | Nucleotide analog composition and synthesis method |
Jul, 2017
(6 years ago) | |
| US6703396 | GILEAD | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar, 2021
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5814639 (Pediatric) | GILEAD | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Mar, 2016
(8 years ago) | |
| US6043230 | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(6 years ago) | |
|
US5914331 (Pediatric) | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jan, 2018
(6 years ago) | |
|
US6043230 (Pediatric) | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(6 years ago) | |
|
US5922695 (Pediatric) | GILEAD | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jan, 2018
(6 years ago) | |
|
US5935946 (Pediatric) | GILEAD | Nucleotide analog composition and synthesis method |
Jan, 2018
(6 years ago) | |
|
US5977089 (Pediatric) | GILEAD | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(6 years ago) | |
| US6642245 | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov, 2020
(3 years ago) | |
|
US6642245 (Pediatric) | GILEAD | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
May, 2021
(2 years ago) | |
|
US6703396 (Pediatric) | GILEAD | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Sep, 2021
(2 years ago) | |
| US9744181 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months ago) | |
| US8716264 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months ago) | |
| US9457036 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months ago) | |
| US8592397 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months ago) | |
|
US8716264 (Pediatric) | GILEAD | Compositions and methods for combination antiviral therapy |
Jul, 2024
(2 months from now) | |
Drugs and Companies using EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient
Market Authorisation Date: 10 March, 2016
Treatment: Treatment of hiv-1 infection in pediatric patients 12 years of age and older; Treatment of hiv infection; Prophylaxis of hiv-1 infection; Treatment of hiv
Dosage: TABLET;ORAL
TRUVADA family patents